

PET-CT REQUEST

PRIOR TO APPOINTMENT FAX OR EMAIL THIS FORM

Ph: 08 9500 8950 Fax: 08 6444 7480 Email: petrockingham@qscan.com.au



 Book online today qscan.com.au/bookings

PATIENT DETAILS

Patient name

Medicare number

Birth date

Phone

Clinical trial / ID number

EXAMINATION

PET with CT PET only

RADIOTRACER

FDG FET FEMPA NaF
 PSMA Amyloid FLT Other

Clinical Indications

Contrast Allergy

Renal Impairment

Surgery / Biopsy

Radiation Therapy

Chemotherapy

MBS Eligible Items

- | | | |
|--|---|--|
| <input type="checkbox"/> 61523 SPN Diagnosis | <input type="checkbox"/> 61571 Uterine Cervix Staging | <input type="checkbox"/> 61610 Metastatic SCC Staging |
| <input type="checkbox"/> 61529 NSCLC Staging | <input type="checkbox"/> 61575 Uterine Cervix Restaging | <input type="checkbox"/> 61620 Lymphoma Staging |
| <input type="checkbox"/> 61538 Brain Restaging | <input type="checkbox"/> 61598 Head & Neck Staging | <input type="checkbox"/> 61622 Lymphoma First Line Surveillance |
| <input type="checkbox"/> 61559 Epilepsy Diagnosis | <input type="checkbox"/> 61604 Head & Neck Restaging | <input type="checkbox"/> 61628 Lymphoma Restaging |
| <input type="checkbox"/> 61541 Colorectal Restaging | <input type="checkbox"/> 61553 Melanoma Restaging | <input type="checkbox"/> 61632 Lymphoma Second Line Surveillance |
| <input type="checkbox"/> 61577 Oesophageal / GOJ Staging | <input type="checkbox"/> 61524 PET Breast Staging | <input type="checkbox"/> 61640 Bone/Soft Tissue Sarcoma Staging |
| <input type="checkbox"/> 61565 Ovarian Restaging | <input type="checkbox"/> 61525 PET Breast Restaging | <input type="checkbox"/> 61646 Sarcoma Restaging |

Referred By

Contact details

Provider number

Send copy to

Date of follow up appointment

Signature

Date

Dr Zeyad Al-Ogaili

(MBCHB, FRANZCR, FRCR, FAANMS)
Qscan Rockingham on-site Radiologist

Qscan Rockingham

2 Civic Boulevard
Rockingham, WA 6168

Lung		
Solitary Pulmonary Nodule Diagnosis	61523	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
NSCLC Staging	61529	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
Brain		
Brain Restaging	61538	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
Epilepsy Diagnosis	61559	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.
Gastrointestinal		
Colorectal Restaging	61541	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
Oesophageal/GOJ Staging	61577	Whole body FDG PET study, performed for the staging of proven oesophageal or GOJ carcinoma, in patients considered suitable for active therapy.
Gynaecology		
Ovarian Restaging	61565	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
Uterine Cervix Staging	61571	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
Uterine Cervix Restaging	61575	Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
Head & Neck		
Head & Neck Staging	61598	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head & neck cancer.
Head & Neck Restaging	61604	Whole body FDG PET study performed for the evaluation of patients with suspected residual head & neck cancer after definitive treatment, and who are suitable for active therapy.
Melanoma		
Melanoma Restaging	61553	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
SCC		
Metastatic SCC unknown primary Staging	61610	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
Lymphoma		
Lymphoma Staging	61620	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma Surveillance	61622	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma Restaging	61628	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
Lymphoma Surveillance	61632	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
Sarcoma		
Bone or Soft Tissue Sarcoma Staging	61640	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
Sarcoma Restaging	61646	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.
Breast		
PET Breast Staging	61524	Whole body FDG PET study, performed for the staging of locally advanced (stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.).
PET Breast Staging	61525	Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.).

Qscan Rockingham

2 Civic Boulevard
Rockingham, WA 6168

Ph: 08 9500 8950 Fax: 08 6444 7480

Email: petrockingham@qscan.com.au

Electronic referrals are also available at qscan.com.au/myresults

